Granexin® gel is a topical formulation of aCT1 developed to address unmet clinical needs within the field of dermatology. Xequel Bio’s dermatology program is currently focused on three main areas: medical countermeasures, cutaneous scarring, and thermal burns. There is an urgent need to bring relief for these patients, and Granexin® gel has been developed to provide that. Late-stage clinical trials are ongoing, with multiple near-term milestones.
Granexin® gel is the flagship product of Xequel Bio, and it shows significant promise in these applications. As a company, we are excited to bring this innovative solution to market to help those who could benefit from its use!
© 2022 Xequel Bio. All rights reserved.